Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety-related claims about benzodiazepines (dependence, withdrawal, abuse/misuse/addiction, and risks consistent with label warnings) are generally supported by the provided XANAX XR excerpts; however, several factual claims (e.g., specific generic manufacturers, patent expiration, brand development) are not supported by the provided prescribing information excerpts and reduce alignment.
Category Scores
Accurate Statements
Alprazolam is a benzodiazepine.
Supported implicitly by the provided label sections repeatedly referring to benzodiazepines including XANAX XR (Warnings/Precautions 5.1-5.3; Drug Interactions 7.1).
Alprazolam carries risks including dependence.
Supported by Dependence and Withdrawal Reactions (5.3).
Alprazolam can cause withdrawal symptoms if stopped abruptly.
Supported by Abrupt discontinuation or rapid dosage reduction precipitating acute withdrawal reactions (5.3), including life-threatening reactions (e.g., seizures).
Alprazolam has potential for abuse.
Supported by Abuse, Misuse, and Addiction (5.2).
In the United States, manufacture, distribution, and prescription of alprazolam are subject to strict regulations by agencies such as the FDA and the DEA.
Not directly supported or contradicted by the provided excerpts; however, this claim is general and not explicitly derivable from the supplied label text.
Unsupported Statements
Alprazolam is manufactured by multiple pharmaceutical companies.
Not supported by the provided XANAX XR prescribing information excerpts.
The active ingredient alprazolam is produced by various generic drug manufacturers.
Not supported by the provided XANAX XR prescribing information excerpts.
Generic alprazolam is formulated into finished dosage forms by different companies.
Not supported by the provided XANAX XR prescribing information excerpts.
Alprazolam is most widely known by the original brand name Xanax.
Not supported by the provided XANAX XR prescribing information excerpts.
Xanax was developed by The Upjohn Company (now part of Pfizer).
Not supported by the provided XANAX XR prescribing information excerpts.
Numerous companies produce generic versions of alprazolam.
Not supported by the provided XANAX XR prescribing information excerpts.
Teva Pharmaceuticals manufactures generic alprazolam.
Not supported by the provided XANAX XR prescribing information excerpts.
Mylan manufactures generic alprazolam.
Not supported by the provided XANAX XR prescribing information excerpts.
Actavis manufactures generic alprazolam.
Not supported by the provided XANAX XR prescribing information excerpts.
Alprazolam is classified as a Schedule IV drug under the Controlled Substances Act in the United States.
Not supported by the provided XANAX XR prescribing information excerpts.
Alprazolam is a controlled substance due to potential for dependence and abuse.
Partially overlaps with dependence/abuse risks, but the provided excerpts do not state the scheduling rationale; not supported as written.
Alprazolam was originally protected by a patent for Xanax that has expired.
Not supported by the provided XANAX XR prescribing information excerpts.
The expiration of patents on the original brand allowed for widespread production of generic versions.
Not supported by the provided XANAX XR prescribing information excerpts.
Side effects of alprazolam can include drowsiness.
Not supported by the provided excerpts (no adverse reaction listing provided beyond references).
Side effects of alprazolam can include dizziness.
Not supported by the provided excerpts.
Side effects of alprazolam can include impaired coordination.
Not supported by the provided excerpts.
Alprazolam is typically prescribed for short-term management of anxiety disorders.
Not supported by the provided excerpts (no indications section text provided).
Alprazolam is typically prescribed for panic disorder.
Not supported by the provided excerpts (no indications section text provided).
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No claim included the label-specific mitigation for opioid co-use (e.g., reserve for inadequate alternatives, lowest effective dose/minimum duration, and close monitoring for respiratory depression/sedation) even though the audit target was opioid co-use risks.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety-related dependence/withdrawal and abuse/misuse statements align with the provided label excerpts, but missing label-specific opioid co-use risk mitigation and multiple unsupported factual claims may reduce reliability; unsupported manufacturer/scheduling/patent claims could mislead readers even if not directly dosing-related.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several factual claims (manufacturers, brand history, patent status, Schedule classification, and specific side effects/indications) are not supported by the provided XANAX XR prescribing information excerpts.
Suggested Improvement
Limit claims to text supported by the provided label excerpts (e.g., dependence/withdrawal, abuse/misuse/addiction, and opioid co-use warnings/mitigation). Remove or qualify unsupported manufacturer, patent, scheduling, and adverse reaction/indication statements unless the corresponding label sections are provided.